Bio-View Ltd
BIOV.TA
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.85M
Close$
$-6445.46
190.9% downside
Current Fair Value
190.9% downsideOvervalued by 190.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.85 Million |
|---|---|
| Enterprise Value | $6.26 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-110 |
| Beta | -0.01 |
| Outstanding Shares | 137,588 |
Return
| Return on Equity | -195.18% |
|---|---|
| Return on Assets | -70.78% |
| Return on Invested Capital | -54.11% |
Valuation & Multiples
| P/E Ratio | -0.75 |
|---|---|
| PEG | 1.53 |
| Price to Sales | 47.27 |
| Price to Book Ratio | 147.71 |
| Enterprise Value to Revenue | 0.3 |
| Enterprise Value to EBIT | -1.31 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.34 |
| Debt to Equity | 0.31 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bio-View Ltd
30 employees
CEO: Daniel Klain Bio-View Ltd, founded in 2000 and headquartered in Rehovot, Israel, is a developer, manufacturer, and global distributor of advanced automated cell imaging and analysis systems. These sophisticated solutions are utilized by clinical and ...